ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer

Share :
Published: 17 Jun 2009
Views: 13190
Rating:
Save
Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US
ASCO press conference: Adding bevacizumab (avastin) to standard adjuvant chemotherapy does not improve disease-free survival for early-stage colon cancer